Filed in archive
Studies
, Treatment
by Gloria Gamat on March 26, 2007
Such were the findings of a two-year study of 242 Japanese elderly men with Parkinson's.
The study found the men taking risedronate were three times less likely to sustain a hip fracture compared to the placebo group.
Researchers also found bone mineral density (BMD) among men taking risedronate increased by 2.2 percent and decreased by nearly three percent in the placebo group.
In addition, researchers found a biomarker for bone loss decreased by nearly 47 percent in the risedronate group and 33 percent in the placebo group.
The said study was led by Yoshihiro Sato, MD, with Mitate Hospital in Tokyo and supported by Takeda Pharmaceuticals, (co-developer of risedronate).
Findings have been reported in Neurology®, the scientific journal of the American Academy of Neurology.
Read the full report.
[article abstract]
[In Photo: Actonel®, a risedronate brand; Photo Credit: How Stuff Works]
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/59786
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Bone Drug Risedronate Prevented Hip Fractures in Parkinson's Disease Patients:
|
Rating: 7.40 out of 5 vote(s) cast.
|
Response from:
Trusted.MD Network
Piercings in the mouth area (tongue, lips) maybe the in thing with teeners. But on a medical standpoint, experts warn that teeth and jewelry don't mix.
© Rodrigo Galindez
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
